Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
You may also be interested in...
With the company’s vaccine candidate in Phase III, Pfizer CEO Albert Bourla says there is pressure to perform because the hopes of the world are on the pharma industry to find a solution to the coronavirus pandemic.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.
Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.